Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Open Labelled, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With Clostridium Difficile-associated Diarrhea (CDAD)

NCT03824795 is registered in ClinicalTrials.gov with MGB Biopharma Limited as lead sponsor.

NCT NCT03824795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03824795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Open Labelled, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With Clostridium Difficile-associated Diarrhea (CDAD)
Lead sponsor
MGB Biopharma Limited
Phase
Phase 2
Overall status
Completed
Start date
February 7, 2019
Completion date
April 3, 2020
Enrollment
34 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection